---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-070127"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:18:02.699182+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q3 revenue $15.1M, down 6% YoY; GAAP loss $0.19/share; FY guidance reaffirmed

## Summary
- Revenue $15.1M (-6% YoY, +8% QoQ); gross margin improved to 62% from 56%.
- GAAP net loss $3.5M ($0.19 per share); non-GAAP net income $1.3M ($0.07 per share).
- Operating cash flow $7.9M in first nine months; cash & investments $78.8M.
- FY2022 guidance reiterated: revenue $62M-$68M, gross margin 59%-62%.
- Repurchased 1.1M shares YTD at average price of $16.70 per share.

## SEC filing metadata
- accession: 0001213900-22-070127
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390022070127/0001213900-22-070127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390022070127/ea168208-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-070127
- JSON: https://secwatch.observer/filing/0001213900-22-070127.json
- Plain text: https://secwatch.observer/filing/0001213900-22-070127.txt

## Key facts
- Earnings Releases
  OptimizeRx Corp reported third quarter ended September 30, 2022 results: revenue $15.1 million, net income $3.5 million or $(0.19) per basic and diluted share, EPS $(0.19). Guidance reaffirmed.
  - Period: third quarter ended September 30, 2022
  - Revenue: $15.1 million
  - Net income: $3.5 million or $(0.19) per basic and diluted share
  - EPS: $(0.19)
  - Guidance: reaffirmed
  - Result: reported results
  source text: OptimizeRx Reports Third Quarter 2022 Financial Results - Q3 Revenue of $15.1 million, down 6% year-over-year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390022070127/0001213900-22-070127-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.